Dynavax Technologies (NASDAQ:DVAX) Stock Passes Above 200 Day Moving Average – Time to Sell?

Dynavax Technologies Corporation (NASDAQ:DVAX) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $11.19 and traded as high as $15.67. Dynavax Technologies shares last traded at $15.63, with a volume of 1,836,179 shares traded.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on DVAX shares. Wall Street Zen raised shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a report on Saturday, December 27th. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research report on Wednesday, October 8th. Finally, William Blair downgraded shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Dynavax Technologies currently has a consensus rating of “Hold” and an average target price of $24.33.

Dynavax Technologies Stock Performance

The company has a market capitalization of $1.84 billion, a P/E ratio of -42.24 and a beta of 0.89. The company has a debt-to-equity ratio of 0.41, a quick ratio of 6.94 and a current ratio of 7.62. The business’s fifty day simple moving average is $12.73 and its 200-day simple moving average is $11.19.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings data on Wednesday, November 5th. The biopharmaceutical company reported $0.21 earnings per share for the quarter, beating analysts’ consensus estimates of $0.14 by $0.07. The firm had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a positive return on equity of 7.18% and a negative net margin of 13.13%. As a group, equities analysts anticipate that Dynavax Technologies Corporation will post 0.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, COO David F. Novack sold 30,000 shares of the company’s stock in a transaction on Wednesday, December 24th. The shares were sold at an average price of $15.49, for a total transaction of $464,700.00. Following the sale, the chief operating officer owned 111,451 shares of the company’s stock, valued at $1,726,375.99. This represents a 21.21% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 2.98% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Exchange Traded Concepts LLC boosted its holdings in shares of Dynavax Technologies by 1.6% in the 4th quarter. Exchange Traded Concepts LLC now owns 204,282 shares of the biopharmaceutical company’s stock worth $3,142,000 after purchasing an additional 3,306 shares during the period. Congress Asset Management Co. lifted its position in Dynavax Technologies by 1.5% in the fourth quarter. Congress Asset Management Co. now owns 233,009 shares of the biopharmaceutical company’s stock worth $3,584,000 after buying an additional 3,434 shares during the last quarter. SG Americas Securities LLC boosted its stake in Dynavax Technologies by 800.5% during the fourth quarter. SG Americas Securities LLC now owns 150,876 shares of the biopharmaceutical company’s stock worth $2,320,000 after buying an additional 134,122 shares during the period. Hudson Bay Capital Management LP boosted its stake in Dynavax Technologies by 11.7% during the third quarter. Hudson Bay Capital Management LP now owns 604,825 shares of the biopharmaceutical company’s stock worth $6,006,000 after buying an additional 63,225 shares during the period. Finally, CIBC Bancorp USA Inc. bought a new position in Dynavax Technologies during the third quarter valued at $109,000. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.